- Suven Pharmaceuticals and Cohance Lifesciences announce merger. The merged entity will have three distinct business units – Pharma CDMO, Spec Chem CDMO, and API+.
- The merger is expected to conclude over the next 12-15 months, subject to shareholder and regulatory approvals.
Suven Pharmaceuticals, has announced a merger with Cohance Lifesciences. The merger was announced on Thursday, and it is expected to conclude over the next 12-15 months, subject to shareholder and regulatory approvals. The combined entity will have three distinct business units – Pharma CDMO, Spec Chem CDMO, and API+ which aim to provide multiple engines of growth, said the company.
“Merger shall establish Suven’s position as a diversified CDMO and API leader in India, transcending our current revenue base. The merged entity is expected to be amongst the leading integrated CDMO players in India. With an expanded capacity to ~2,650 kL and a significantly broadened customer base, scale and synergy benefits are substantial,” the company said in a statement.
“The anticipated synergy benefits from our merger with Cohance are substantial. On the revenue front, the limited customer overlap will help with cross-selling opportunities, leveraging Cohance’s capabilities to reach Suven customers and vice versa, e.g. leverage ADC platform and lifecycle management of key molecules for Suven customers,” it added.
Overview of outsourcing trends 
